Interestingly, analysis of TRIM21 expression in The Cancer Genome Atlas database from cBioPortal (https://www.cbioportal.org/) showed that low TRIM21 expression in several types of tumors was significantly associated with poor clinical outcomes in patients with mutp53 cancers but not wtp53 cancers, including rectal adenocarcinoma, stomach adenocarcinoma, and kidney chromophobe (Figure 6D), as well as breast invasive ductal carcinoma (Supplemental Figure 6). Here, TRIM21 is linked to invasive ductal breast carcinoma.